Antony R. Horton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Antony R. Horton has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alun Millward Davies
School of Biosciences Cardiff University Cardiff UK
3 shared publications Howard M. Fillit
2 shared publications- Howard M. Fillit
Alzheimer's Drug Discovery Foundation, New York, NY, USA
2 shared publications Ai Shih
1 shared publication- Alan K. Percy
Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Division of Pediatric Neurology, Children's of Alabama, Birmingham, Alabama
1 shared publication Anna Buj-Bello
School of Biological and Medical Sciences, University of St. Andrews, Fife, Scotland
1 shared publication
Latest Publications
- 28 January 2011
- Published by Wiley in Alzheimer's & Dementia
- Vol. 7 (2) , 142-150
An analysis of global research funding for the frontotemporal dementias: 1998–2008
Background: To better understand the status of frontotemporal dementia (FTD) research, and identify opportunities to accelerate translational research, we analyzed international funding for FTD and related dementias between 1998 and 2008.Methods: Search terms were compiled to define the clinical spectrum of FTD and all known mechanisms. Funders were asked to return grants that contained these search terms in the title or Grants were classified according to the most reasonably achieved stated aim using a classification scheme of research activities that was developed to map grants along the continuum from basic research to clinical trials of treatments.Results: This analysis captured 613 grants ($432,167,275), from 19 private and public funders from 7 countries and the European Union. National Institutes of Health contributed $360 million (MM), 53% of grants and 83% of total funding. Foundations contributed $43 MM, 35% of grants and 10% of total funding, an increase in recent years. A total of $319 MM (74%, funding) went toward basic research, of which 10% was dedicated to preclinical treatment development, clinical treatment evaluation, and developing detection, diagnostic, and imaging technologies and reagents.Conclusions: FTD received moderate funding over the past decade, which has decreased almost five‐fold during this period. A sizable proportion of FTD funding supported mechanisms shared with Alzheimer's disease. Few programs advanced past validating target models and into drug discovery and preclinical development, indicating that the knowledge gained from recent research has still not advanced into treatment development. Quantitative analysis of funding highlighted under‐resourced areas as well as redundant efforts, enabling a more strategic approach toward advancing FTD drug discovery and development.
- 28 January 2011
- Published by Wiley in Alzheimer's & Dementia
- Vol. 7 (2) , 142-150
An analysis of global research funding for the frontotemporal dementias: 1998–2008
Background: To better understand the status of frontotemporal dementia (FTD) research, and identify opportunities to accelerate translational research, we analyzed international funding for FTD and related dementias between 1998 and 2008.Methods: Search terms were compiled to define the clinical spectrum of FTD and all known mechanisms. Funders were asked to return grants that contained these search terms in the title or Grants were classified according to the most reasonably achieved stated aim using a classification scheme of research activities that was developed to map grants along the continuum from basic research to clinical trials of treatments.Results: This analysis captured 613 grants ($432,167,275), from 19 private and public funders from 7 countries and the European Union. National Institutes of Health contributed $360 million (MM), 53% of grants and 83% of total funding. Foundations contributed $43 MM, 35% of grants and 10% of total funding, an increase in recent years. A total of $319 MM (74%, funding) went toward basic research, of which 10% was dedicated to preclinical treatment development, clinical treatment evaluation, and developing detection, diagnostic, and imaging technologies and reagents.Conclusions: FTD received moderate funding over the past decade, which has decreased almost five‐fold during this period. A sizable proportion of FTD funding supported mechanisms shared with Alzheimer's disease. Few programs advanced past validating target models and into drug discovery and preclinical development, indicating that the knowledge gained from recent research has still not advanced into treatment development. Quantitative analysis of funding highlighted under‐resourced areas as well as redundant efforts, enabling a more strategic approach toward advancing FTD drug discovery and development.
- Open Access
- 24 September 2009
- Published by Springer Nature in Journal of Neurodevelopmental Disorders
- Vol. 1 (4) , 313-317
Variable phenotypic expression of a MECP2 mutation in a family
We report a three generation family in which five members, three females and two males, demonstrate a 44 bp deletion (1164–1207del44) in the MECP2 gene associated with Rett syndrome, leading to a truncation of the C-terminus of the protein. Two of the three females and both males do not meet RTT criteria whereas the youngest female has classic RTT. Both males demonstrated a clear pattern of progressive involvement including dystonia. The transmitting females do not demonstrate features of RTT as a result of unbalanced X chromosome inactivation (XCI) and were only identified as carriers following the evaluation of the affected males and the girl with classic RTT. As such, accurate assessment of the precise frequency of MECP2 mutations in carrier females with mild cognitive impairment or borderline cognitive function will be under-represented unless an affected offspring is recognized. Strategies for accurate diagnosis in such instances should be considered carefully.
- 24 September 2009
- Published by Springer Nature in Journal of Neurodevelopmental Disorders
- Vol. 1 (4) , 313-317
Open AccessVariable phenotypic expression of a MECP2 mutation in a family
We report a three generation family in which five members, three females and two males, demonstrate a 44 bp deletion (1164–1207del44) in the MECP2 gene associated with Rett syndrome, leading to a truncation of the C-terminus of the protein. Two of the three females and both males do not meet RTT criteria whereas the youngest female has classic RTT. Both males demonstrated a clear pattern of progressive involvement including dystonia. The transmitting females do not demonstrate features of RTT as a result of unbalanced X chromosome inactivation (XCI) and were only identified as carriers following the evaluation of the affected males and the girl with classic RTT. As such, accurate assessment of the precise frequency of MECP2 mutations in carrier females with mild cognitive impairment or borderline cognitive function will be under-represented unless an affected offspring is recognized. Strategies for accurate diagnosis in such instances should be considered carefully.
- 10 November 2008
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 4 (5) , 501-502
Editorial [ Drug Discovery for Alzheimer's Disease: Filling the Pipeline Guest Editors: Antony R. Horton and Howard M. Fillit ]
- 10 November 2008
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 4 (5) , 501-502
Editorial [ Drug Discovery for Alzheimer's Disease: Filling the Pipeline Guest Editors: Antony R. Horton and Howard M. Fillit ]
- 1 December 2007
- Vol. 4 (5)
Drug discovery for Alzheimer's disease: filling the pipeline.
- 1 December 2007
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 4 (5) , 501-502
Editorial [ Drug Discovery for Alzheimers Disease: Filling the Pipeline Guest Editors: Antony R. Horton and Howard M. Fillit ]
- 1 December 2007
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 4 (5) , 501-502
Editorial [ Drug Discovery for Alzheimers Disease: Filling the Pipeline Guest Editors: Antony R. Horton and Howard M. Fillit ]
- 1 February 1998
- Published by Wiley in European Journal of Neuroscience
- Vol. 10 (2) , 673-679
Cytokines promote the survival of mouse cranial sensory neurones at different developmental stages
To investigate when the neurotrophic cytokines ciliary neurotrophic factor (CNTF), leukaemia inhibitory factor (LIF), oncostatin-M (OSM), interleukin-6 (IL-6) and cardiotrophin-1 (CT-1) act on developing sensory neurones and whether they co-operate with neurotrophins in regulating neuronal survival, we studied the in vitro trophic effects of these factors on two well-characterized populations of cranial sensory neurones at closely staged intervals throughout embryonic development. The cutaneous sensory neurones of the trigeminal ganglion, which show an early, transient survival response to BDNF and NT3 before becoming NGF-dependent, were supported by CNTF, LIF, OSM and CT-1 during the late fetal period, several days after the neurones become NGF-dependent. At this stage of development, these cytokines promoted the survival of a subset of NGF-responsive neurones. The enteroceptive neurones of the nodose ganglion, which retain dependence on BDNF throughout fetal development, were supported throughout their development by CNTF, LIF, OSM and CT-1, and displayed an additional survival response to IL-6 in the late fetal period. These findings indicate that populations of sensory neurones display different developmental patterns of cytokine responsiveness and show that embryonic trigeminal neurones pass through several phases of differing neurotrophic factor survival requirements.
- 1 February 1998
- Published by Wiley in European Journal of Neuroscience
- Vol. 10 (2) , 673-679
Cytokines promote the survival of mouse cranial sensory neurones at different developmental stages
To investigate when the neurotrophic cytokines ciliary neurotrophic factor (CNTF), leukaemia inhibitory factor (LIF), oncostatin-M (OSM), interleukin-6 (IL-6) and cardiotrophin-1 (CT-1) act on developing sensory neurones and whether they co-operate with neurotrophins in regulating neuronal survival, we studied the in vitro trophic effects of these factors on two well-characterized populations of cranial sensory neurones at closely staged intervals throughout embryonic development. The cutaneous sensory neurones of the trigeminal ganglion, which show an early, transient survival response to BDNF and NT3 before becoming NGF-dependent, were supported by CNTF, LIF, OSM and CT-1 during the late fetal period, several days after the neurones become NGF-dependent. At this stage of development, these cytokines promoted the survival of a subset of NGF-responsive neurones. The enteroceptive neurones of the nodose ganglion, which retain dependence on BDNF throughout fetal development, were supported throughout their development by CNTF, LIF, OSM and CT-1, and displayed an additional survival response to IL-6 in the late fetal period. These findings indicate that populations of sensory neurones display different developmental patterns of cytokine responsiveness and show that embryonic trigeminal neurones pass through several phases of differing neurotrophic factor survival requirements.
- 1 January 1997
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 10 (3-4) , 162-172
NGF Binding to p75 Enhances the Sensitivity of Sensory and Sympathetic Neurons to NGF at Different Stages of Development
- 1 January 1997
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 10 (3-4) , 162-172
NGF Binding to p75 Enhances the Sensitivity of Sensory and Sympathetic Neurons to NGF at Different Stages of Development